NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview
Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Schwartz focused the discussion on these companies, offering brief insight into the operations of Skyline Medical and noting that the purpose of TumorGenesis was to develop a lab media to replace rats and mice in the scientific industries and in the testing of tumors, which the company has done. The next step, said Schwartz, is to get the kits out so people can use it, an effort that is “coming along handsomely.” In addition, Schwartz discussed Soluble Biotech, POAI’s newest subsidiary. Schwartz noted that the company is two labs “that we put together” and moved into a research park, quadrupling the working space. Schwartz explained that “the technology used by Soluble is proprietary. These machines . . . are the only machines of their kind. In the determination of solubility of products, they work wonders in that area.” Schwartz also discussed Helomics.
“The original basis of Helomics. . . was that physicians or hospitals would send their tumors to this company, and they would test the tumors with the known therapies of the day. . . . In that process, [Helomics] accumulated over 150,000 tumors covering over 137 different cancers. . . . That database is the largest of its kind in the world. . . .With that data, and the fact that we’ve sequenced these tumors, we have shown that we can provide quality information to anyone who needs it. There’s a lot going on at Helomics. We think we’ve validated the company. We’ve got assets that are one-of-a-kind in the world, and we think we are on our way to where we wanted to be when we first purchased this company a couple of years ago.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Schwartz focused the discussion on these companies, offering brief insight into the operations of Skyline Medical and noting that the purpose of TumorGenesis was to develop a lab media to replace rats and mice in the scientific industries and in the testing of tumors, which the company has done. The next step, said Schwartz, is to get the kits out so people can use it, an effort that is “coming along handsomely.” In addition, Schwartz discussed Soluble Biotech, POAI’s newest subsidiary. Schwartz noted that the company is two labs “that we put together” and moved into a research park, quadrupling the working space. Schwartz explained that “the technology used by Soluble is proprietary. These machines . . . are the only machines of their kind. In the determination of solubility of products, they work wonders in that area.” Schwartz also discussed Helomics.
“The original basis of Helomics. . . was that physicians or hospitals would send their tumors to this company, and they would test the tumors with the known therapies of the day. . . . In that process, [Helomics] accumulated over 150,000 tumors covering over 137 different cancers. . . . That database is the largest of its kind in the world. . . .With that data, and the fact that we’ve sequenced these tumors, we have shown that we can provide quality information to anyone who needs it. There’s a lot going on at Helomics. We think we’ve validated the company. We’ve got assets that are one-of-a-kind in the world, and we think we are on our way to where we wanted to be when we first purchased this company a couple of years ago.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
